Table 2.
Previous reports of pancreatic cancer concomitant with IPMN
| Author (Year) | No. cases with IPMN | PC concomitant with IPMN | Frequency (%) | Follow‐up period (years) |
|---|---|---|---|---|
| Yamaguchi et al. (2002)19 | 76 | 7 | 9.2 | no data |
| Tada et al. (2006)16 | 197a | 5 | 2.6 | 3.8 |
| Hanada et al. (2006)20 | 60 | 2 | 3.3 | 2 |
| Uehara et al. (2008)15 | 60 | 5 | 8 | 7.3 |
| Ingakul et al. (2010)21 | 236 | 22 | 9.3 | no data |
| Tanno et al. (2010)22 | 168 | 9 | 5.4 | no data |
| Ikeuchi et al. (2010)23 | 145 | 5 | 3.4 | 4.6 |
| Kanno et al. (2010)24 | 159 | 7 | 4.4 | no data |
| Sawai et al. (2010)25 | 103 | 2 | 1.9 | 4.9 |
| Kawakubo et al. (2011)26 | 642 | 17 | 2.6 | 4.8 |
| Maguchi et al. (2011)17 | 349 | 7 | 2 | 3.7 |
| Yamaguchi et al. (2011)18 | 765 | 31 | 4.1 | no data |
| Ohno et al. (2011)27 | 142 | 2 | 1.4 | 3.5 |
| Ohtsuka et al. (2013)28 | 179 | 20 | 11.2 | no data |
| Kamata et al. (2014)29 | 167 | 18 | 10.8 | 3.5 |
| Crippa et al. (2017)30 | 281 | 3 | 1.1 | 4.3 |
a
No. cases included intraductal papillary mucinous neoplasm (IPMN) and cystic regions.